Clinical Trial

A 16-Week, Single-Blind Randomized, Placebo- Controlled Food Study of the Safety and Tolerability of AXA1125 and AXA1957 in Subjects with Non-Alcoholic Fatty Liver Disease (NAFLD)

Study Status:

Contact Information:

Please contact us for more information or to learn if you are eligible to participate.

Study Purpose

The intention and objective of this study is to primarily understand the safety and tolerability profile of AXA1125 and AXA1957 when administered to subjects with NAFLD. The study would also add to the body of knowledge regarding the role(s) of amino acids in hepatic physiology.

Information

Principal Investigator Rashmee Patil, MD
Co-PI
Sponsor Axcella Health Inc.
Type of Trial Interventional